[go: up one dir, main page]

CA2362697A1 - Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments - Google Patents

Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments Download PDF

Info

Publication number
CA2362697A1
CA2362697A1 CA002362697A CA2362697A CA2362697A1 CA 2362697 A1 CA2362697 A1 CA 2362697A1 CA 002362697 A CA002362697 A CA 002362697A CA 2362697 A CA2362697 A CA 2362697A CA 2362697 A1 CA2362697 A1 CA 2362697A1
Authority
CA
Canada
Prior art keywords
benzazocin
methano
ols
hexahydro
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002362697A
Other languages
French (fr)
Other versions
CA2362697C (en
Inventor
Matthias Grauert
Hans Briem
Matthias Hoffmann
Adrian Carter
Thomas Weiser
Wolf-Dietrich Bechtel
Rainer Palluk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2362697A1 publication Critical patent/CA2362697A1/en
Application granted granted Critical
Publication of CA2362697C publication Critical patent/CA2362697C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to N-(5-phenyl--tetrahydrofuranyl)methyl- and N-(6-phenyl--tetrahydropyranyl)methyl substituted 1,2,3,4,5,6-hexahydro--2,6-methano-3-benzazocin-10-ols of general formula (1) (see formula 1) to a method for producing them and to their use as medicaments with sodium channel blocking activity, and related therapeutic functions.
CA002362697A 1999-02-23 2000-02-12 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments Expired - Fee Related CA2362697C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19907874.2 1999-02-23
DE19907874A DE19907874A1 (en) 1999-02-23 1999-02-23 New N-substituted hexahydro-2,6-methano-3-benzazocin-10-ol derivatives, as tension-dependent sodium channel blockers useful for treating e.g. arrhythmia, spasms, pain or neurodegenerative diseases
PCT/EP2000/001160 WO2000050421A1 (en) 1999-02-23 2000-02-12 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments

Publications (2)

Publication Number Publication Date
CA2362697A1 true CA2362697A1 (en) 2000-08-31
CA2362697C CA2362697C (en) 2008-04-22

Family

ID=7898638

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362697A Expired - Fee Related CA2362697C (en) 1999-02-23 2000-02-12 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments

Country Status (14)

Country Link
EP (1) EP1157020B1 (en)
JP (1) JP2002537393A (en)
AR (1) AR022718A1 (en)
AT (1) ATE224890T1 (en)
AU (1) AU2910900A (en)
CA (1) CA2362697C (en)
CO (1) CO5170499A1 (en)
DE (2) DE19907874A1 (en)
DK (1) DK1157020T3 (en)
ES (1) ES2183786T3 (en)
PE (1) PE20001487A1 (en)
PT (1) PT1157020E (en)
UY (1) UY26022A1 (en)
WO (1) WO2000050421A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957156A1 (en) * 1999-11-27 2001-05-31 Boehringer Ingelheim Pharma New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders
US6355652B1 (en) 1999-11-27 2002-03-12 Boehringer Ingelheim Pharma Kg Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10204276A1 (en) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceuticals
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
JP5769970B2 (en) * 2007-11-16 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aryl- and heteroarylcarbonyl derivatives of benzomorphan and related skeletons, medicaments containing such compounds and their use
JP7289119B2 (en) * 2019-02-15 2023-06-09 国立大学法人千葉大学 Method for Synthesizing Optically Active Substituted Tetrahydrofuran Derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575009A (en) * 1976-06-21 1980-09-17 Acf Chemiefarma Nv 6,7-benzomorphan derivatives
AU524600B2 (en) * 1976-09-22 1982-09-23 Sterling Drug Inc. 2,6-methano-3-benzazocines
JPS5513253A (en) * 1978-07-15 1980-01-30 Res Inst For Prod Dev Cis-3-aralkyl substituted-8-benzoylthio-6,11-dimethyl-2,6- methano-1,2,3,4,5,6-hexahydro-3-benzazocine or its acid addition salt
DE3839659A1 (en) * 1988-11-24 1990-05-31 Boehringer Ingelheim Kg USE OF BENZOMORPHANES FOR CYTOPROTECTION

Also Published As

Publication number Publication date
DE19907874A1 (en) 2000-08-24
CO5170499A1 (en) 2002-06-27
ATE224890T1 (en) 2002-10-15
AU2910900A (en) 2000-09-14
AR022718A1 (en) 2002-09-04
UY26022A1 (en) 2000-09-29
ES2183786T3 (en) 2003-04-01
EP1157020B1 (en) 2002-09-25
CA2362697C (en) 2008-04-22
EP1157020A1 (en) 2001-11-28
JP2002537393A (en) 2002-11-05
DK1157020T3 (en) 2003-01-27
DE50000560D1 (en) 2002-10-31
PE20001487A1 (en) 2001-01-18
WO2000050421A1 (en) 2000-08-31
PT1157020E (en) 2003-01-31

Similar Documents

Publication Publication Date Title
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HUS1600022I1 (en) 6-position substituted indoline, production and use thereof as a medicament
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
MX9700885A (en) New heteroaryloxazolidinones.
GB9914486D0 (en) Medicaments
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
PT1589007E (en) 5-membered heterocycle derivatives, production thereof and their use as medicaments
AP2002002637A0 (en) Novel piperazine
AU5485698A (en) Oxyiminopregnancarbolactone
CA2362760A1 (en) Camptothecin derivatives having antitumor activity
MY134880A (en) Thiazolyl amide derivatives
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
AU3850600A (en) Dalda analogs and their use
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
SI1268522T1 (en) Novel lhrh-antagonists, production and use thereof as medicament
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2362697A1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments
CA2256007A1 (en) Substituted heterocyclic benzocycloalkenes and their use as analgesic
AU3660700A (en) N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof
WO2000059862A3 (en) Processes for preparing pesticidal intermediates
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
WO2001004112A3 (en) Benzofurane derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed